David Morris Sells 187,855 Shares of Guardian Pharmacy Services (NYSE:GRDN) Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN) insider David Morris sold 187,855 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $5,575,536.40. Following the completion of the sale, the insider owned 254,472 shares of the company’s stock, valued at $7,552,728.96. The trade was a 42.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Guardian Pharmacy Services Price Performance

Shares of Guardian Pharmacy Services stock opened at $35.41 on Friday. The business has a 50-day simple moving average of $32.74 and a 200 day simple moving average of $29.91. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of 45.98 and a beta of 0.86. Guardian Pharmacy Services, Inc. has a one year low of $19.17 and a one year high of $38.12.

Guardian Pharmacy Services (NYSE:GRDN) last issued its earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.10. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.The company had revenue of $397.62 million for the quarter, compared to analyst estimates of $390.04 million. The firm’s revenue was up 17.4% compared to the same quarter last year. On average, sell-side analysts expect that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Stephens increased their price objective on Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 14th. Oppenheimer raised their price target on shares of Guardian Pharmacy Services from $35.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 18th. Raymond James Financial reiterated an “outperform” rating and issued a $40.00 price objective on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Finally, Truist Financial boosted their target price on Guardian Pharmacy Services from $34.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Guardian Pharmacy Services has a consensus rating of “Buy” and an average target price of $38.00.

Key Headlines Impacting Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: Q3 / latest quarter: GRDN beat EPS and revenue estimates (revenue +17.4% YoY), which supports growth expectations. MarketBeat GRDN summary
• Positive Sentiment: Analyst momentum: several firms (Truist, Raymond James, Oppenheimer, Stephens, Zacks) have raised targets or ratings recently, leaving a buy/strong-buy consensus and a ~$38 average target. Analyst coverage
• Neutral Sentiment: Institutional holders: several funds (Vanguard, Wellington, Brown Advisory, Franklin, Valiant) have recently adjusted positions; this shows continuing institutional interest but mixed flows. Holders data
• Neutral Sentiment: Market writeups flagged “major insider exodus,” useful for context but not new filings by itself. TipRanks article
• Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — a large block that likely pressured the stock. SEC filing
• Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — another very large director sale. SEC filing
• Negative Sentiment: Director John Ackerman sold 1,103,364 shares at ~$29.68 (~$32.7M), a ~76% reduction in his stake. SEC filing
• Negative Sentiment: Officer Fred Burke sold 671,432 shares at ~$29.68 (~$19.9M), a ~44% cut to his position. SEC filing
• Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at ~$29.68 (~$10.3M), reducing her holding by ~43%. SEC filing
• Negative Sentiment: Insider David K. Morris sold 187,855 shares at ~$29.68 (~$5.6M), cutting his position by ~42%. SEC filing
• Negative Sentiment: Major shareholder Equity Fund L.P. (Cardinal) sold 275,728 shares at ~$29.68 (~$8.2M), a ~44% stake reduction — signals significant institutional unloading. SEC filing

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GRDN. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Guardian Pharmacy Services during the 1st quarter worth approximately $233,000. Envestnet Asset Management Inc. lifted its stake in Guardian Pharmacy Services by 7.1% in the second quarter. Envestnet Asset Management Inc. now owns 12,126 shares of the company’s stock valued at $258,000 after purchasing an additional 805 shares during the last quarter. Geode Capital Management LLC lifted its stake in Guardian Pharmacy Services by 65.9% in the second quarter. Geode Capital Management LLC now owns 336,701 shares of the company’s stock valued at $7,177,000 after purchasing an additional 133,715 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its holdings in Guardian Pharmacy Services by 76.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company’s stock valued at $52,000 after purchasing an additional 1,062 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Guardian Pharmacy Services in the second quarter worth $346,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.